Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
Abstract Purpose: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). Methods: Retrospective case series involving six patients with npAIR, taking either rituximab and bortez...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2022-11-01
|
| Series: | Journal of Ophthalmic & Vision Research |
| Subjects: | |
| Online Access: | https://doi.org/10.18502/jovr.v17i4.12304 |
| _version_ | 1798006192755179520 |
|---|---|
| author | Arash Maleki Amanda Colombo Sydney Look-Why BA; Peter Y Chang Stephen D Anesi Stephen D Anesi |
| author_facet | Arash Maleki Amanda Colombo Sydney Look-Why BA; Peter Y Chang Stephen D Anesi Stephen D Anesi |
| author_sort | Arash Maleki |
| collection | DOAJ |
| description | Abstract Purpose: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). Methods: Retrospective case series involving six patients with npAIR, taking either rituximab and bortezomib combination therapy (three cases) or rituximab monotherapy (one case and two historical patients). Results: Patients on both treatment regimens showed stability in most of the visual function parameters during the one year of follow-up. Combination therapy resulted in improvement of scotopic combined rod and cone a-wave and b-wave amplitudes in all eyes where they were available (four eyes); however, rituximab monotherapy resulted in only two eyes with stable scotopic combined rod and cone a-wave and b-wave amplitudes, while four eyes showed a decrease in both a- and b-wave amplitudes. The average improvement in b-wave amplitude (50.7% ± 29.4% [range, 25–90%]) was higher than the average improvement in a-wave amplitude (35.7% ± 9.74 [range, 25–63%]). No severe adverse effects were reported. Conclusion: Rituximab and bortezomib combination therapy may not be more effective than rituximab monotherapy in npAIR patients for most of the visual function parameters; however, this combination therapy may be more effective in improving scotopic combined rod and cone a- and b-wave amplitudes. This may indicate the higher efficacy of combination therapy when there is involvement of the inner retina. |
| first_indexed | 2024-04-11T12:50:59Z |
| format | Article |
| id | doaj.art-b7da2c135bfc4d7d94662c78a613e6d1 |
| institution | Directory Open Access Journal |
| issn | 2008-2010 2008-322X |
| language | English |
| last_indexed | 2024-04-11T12:50:59Z |
| publishDate | 2022-11-01 |
| publisher | Knowledge E |
| record_format | Article |
| series | Journal of Ophthalmic & Vision Research |
| spelling | doaj.art-b7da2c135bfc4d7d94662c78a613e6d12022-12-22T04:23:12ZengKnowledge EJournal of Ophthalmic & Vision Research2008-20102008-322X2022-11-0117451552810.18502/jovr.v17i4.12304jovr.v17i4.12304Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune RetinopathyArash Maleki0Amanda Colombo1Sydney Look-Why2BA; Peter Y Chang3Stephen D Anesi4Stephen D Anesi5 Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA Massachusetts Eye Research and Surgery Institution, Waltham, MA, USAAbstract Purpose: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). Methods: Retrospective case series involving six patients with npAIR, taking either rituximab and bortezomib combination therapy (three cases) or rituximab monotherapy (one case and two historical patients). Results: Patients on both treatment regimens showed stability in most of the visual function parameters during the one year of follow-up. Combination therapy resulted in improvement of scotopic combined rod and cone a-wave and b-wave amplitudes in all eyes where they were available (four eyes); however, rituximab monotherapy resulted in only two eyes with stable scotopic combined rod and cone a-wave and b-wave amplitudes, while four eyes showed a decrease in both a- and b-wave amplitudes. The average improvement in b-wave amplitude (50.7% ± 29.4% [range, 25–90%]) was higher than the average improvement in a-wave amplitude (35.7% ± 9.74 [range, 25–63%]). No severe adverse effects were reported. Conclusion: Rituximab and bortezomib combination therapy may not be more effective than rituximab monotherapy in npAIR patients for most of the visual function parameters; however, this combination therapy may be more effective in improving scotopic combined rod and cone a- and b-wave amplitudes. This may indicate the higher efficacy of combination therapy when there is involvement of the inner retina.https://doi.org/10.18502/jovr.v17i4.12304autoimmune retinopathybortezomibelectroretinographynon-paraneoplastic airrituximabvisual field |
| spellingShingle | Arash Maleki Amanda Colombo Sydney Look-Why BA; Peter Y Chang Stephen D Anesi Stephen D Anesi Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy Journal of Ophthalmic & Vision Research autoimmune retinopathy bortezomib electroretinography non-paraneoplastic air rituximab visual field |
| title | Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy |
| title_full | Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy |
| title_fullStr | Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy |
| title_full_unstemmed | Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy |
| title_short | Rituximab Monotherapy versus Rituximab and
Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy |
| title_sort | rituximab monotherapy versus rituximab and bortezomib combination therapy for treatment of non paraneoplastic autoimmune retinopathy |
| topic | autoimmune retinopathy bortezomib electroretinography non-paraneoplastic air rituximab visual field |
| url | https://doi.org/10.18502/jovr.v17i4.12304 |
| work_keys_str_mv | AT arashmaleki rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy AT amandacolombo rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy AT sydneylookwhy rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy AT bapeterychang rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy AT stephendanesi rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy AT stephendanesi rituximabmonotherapyversusrituximabandbortezomibcombinationtherapyfortreatmentofnonparaneoplasticautoimmuneretinopathy |